

表 2-2 内分泌かく乱化学物質と子宮体がんに関する症例対照研究

		血清レベルの比較			カテゴリー毎のオッズ比				
地域・対象者数	化合物	症例	対照	P値	1(低)	2	3	4 (高)	P trend
Sturgeon, 1998		中央値 (ng/g lipid)							
米国5地域 症例90 住民対照90	p,p'-DDE	1417	1358	0.58	1.0	0.5(0.2-1.2)	1.0(0.4-2.5)	0.7(0.2-2.0)	
	o,p'-DDT	11	19	0.09	1.0	0.9(0.4-2.1)	0.5(0.1-1.9)		
	p,p'-DDT	69	0	0.03	1.0	0.6(0.2-1.6)	1.8(0.7-4.4)		
	Tatal PCBs	302	350	0.48	1.0	1.1(0.4-3.0)	0.7(0.3-2.0)	0.9(0.4-2.5)	
	Estrogenic PCB ¹⁾	1	1	0.84	1.0	1.1(0.5-2.4)	1.3(0.5-3.2)		
	Antiestrogenic PCB ²⁾	166	176	0.86	1.0	1.2(0.5-3.2)	1.2(0.4-3.0)	1.1(0.4-3.1)	
	Enzyme-inducing PCB ³⁾	81	102	0.08	1.0	0.6(0.2-1.5)	0.7(0.3-1.8)	0.6(0.2-1.6)	
	Beta-HCH	38	35	0.37	1.0	0.8(0.3-2.3)	0.5(0.1-1.4)	0.9(0.3-2.6)	
	Dieldrin	8	0	0.03	1.0	2.1(0.9-4.2)	1.9(0.7-4.8)		
	HCB	43	45	0.32	1.0	0.6(0.2-1.8)	0.5(0.2-1.7)	0.8(0.2-2.6)	
	Heptachlor epoxide	0	0	0.08	1.0	0.6(0.3-4.6)	1.2(0.5-3.0)		
	Oxychlordane	0	1	0.56	1.0	0.6(0.2-1.5)	0.7(0.3-1.9)		
	Trans-nonachlor	2	10	0.54	1.0	0.6(0.2-2.0)	1.0(0.4-2.7)		
Weiderpass, 2000		中央値 (ng/g lipid)							
スエーデン 症例154 住民対照205	p,p'-DDT	17.8	13.9	0.01	1.0	1.1(0.6-2.2)	0.8(0.4-1.6)	1.1(0.5-2.1)	0.95
	o,p'-DDT	2	2	0.37					
	p,p'-DDE	582.5	497	0.04	1.0	0.9(0.5-1.8)	1.1(0.6-2.0)	1.0(0.6-2.0)	0.78
	p,p'-DDD	2	2	0.84					
	HCB	66.8	64.9	0.08	1.0	1.2(0.6-2.2)	1.0(0.5-1.9)	1.0(0.5-1.9)	0.76
	Alfa-HCH	1	1	0.81					
	Beta-HCH	57.8	51.1	0.02	1.0	0.8(0.4-1.5)	1.0(0.5-2.0)	0.9(0.5-1.9)	0.87
	Gamma-HCH	1	1	0.17					
	Oxychlordane	14.4	12.8	0.01	1.0	1.1(0.6-2.2)	1.0(0.5-2.0)	1.4(0.7-2.8)	0.33
	Trans-nonachlor	25.0	22.5	0.06	1.0	1.2(0.6-2.3)	1.3(0.7-2.7)	1.2(0.6-2.5)	0.56
	PCB28	3.8	3.0	0.02					
	PCB52	1	1	0.45					
	PCB101	1	1	0.10					
	PCB105	6.1	5.6	0.14	1.0	1.2(0.6-2.3)	1.0(0.5-1.8)	0.8(0.4-1.6)	0.42
	PCB118	50.2	43.0	0.01	1.0	0.6(0.8-3.0)	1.2(0.6-2.4)	1.4(0.7-2.8)	0.58
	PCB138	107.5	101	0.30	1.0	0.8(0.4-1.6)	1.2(0.6-2.2)	0.9(0.5-1.7)	0.95
	PCB153	226.5	223	0.74	1.0	0.9(0.5-1.7)	1.2(0.6-2.2)	0.9(0.5-1.7)	0.94

PCB156	17.4	18.1	0.75	1.0	1.6(0.8-2.9)	1.4(0.7-2.6)	1.0(0.5-2.0)	0.90
PCB167	9.3	8.7	0.06	1.0	2.0(1.0-3.9)	1.4(0.7-2.9)	1.9(0.9-3.9)	0.24
PCB180	147	152	0.80	1.0	1.1(0.6-2.0)	1.1(0.6-2.2)	1.2(0.6-2.2)	0.67
All PCBs ⁴⁾				1.0	1.1(0.6-2.2)	1.1(0.6-2.2)	1.2(0.6-2.2)	0.72
Estrogenic compounds ⁵⁾				1.0	1.1(0.6-2.1)	0.9(0.4-1.7)	1.1(0.6-2.2)	0.90
Antiestrogenic compounds ⁶⁾				1.0	1.7(0.9-3.3)	1.4(0.7-2.8)	1.5(0.7-3.0)	0.48
Compounds with no known hormonal effect ⁷⁾				1.0	1.2(0.6-2.2)	1.4(0.7-2.7)	1.3(0.7-2.4)	0.39

1) PCB 52, 101, 187, 177, 201.

2) PCB 66, 74, 105, 118, 156, 138.

3) PCB 99, 153, 203, 183.

4) PCB 28, 52, 101, 105, 118, 138, 153, 156, 167, 180.

5) o,p'-DDT, p,p'-DDT, p,p'-DDD, beta-HCH, gamma-HCH, trans-nonachlor, oxychlordane, PCB 28, 52, 101, 153.

6) PCB 105, 118, 156, 167.

7) p,p'-DDE, alfa-HCH, HCB, PCB 138, 180.